Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients
| Autor: | H, Ohuchi, K, Noguchi, Y, Kinoshita, M, Hosaka, C, Kawasaki, T, Miura, I, Kondo, M, Harada |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Aged
80 and over Male Antineoplastic Agents Hormonal Chlormadinone Acetate Progesterone Congeners Premedication Prostatic Neoplasms Luteinizing Hormone Middle Aged Prostate-Specific Antigen Humans Testosterone Prospective Studies Leuprolide Neoplasm Recurrence Local Diethylstilbestrol Aged Autacoids |
| Zdroj: | Hinyokika kiyo. Acta urologica Japonica. 46(8) |
| ISSN: | 0018-1994 |
| Popis: | To determine whether administration of estrogen or gestagen prior to luteinizing hormone-releasing hormone (LH-RH) agonist prevents disease flare in prostate cancer patients, we pretreated the patients with either diethylstilbestrol diphosphate (DES-P) 300 mg daily (N = 17) or chlormadinone acetate (CMA) 100 mg daily (N = 16) or none (N = 16) for two weeks before the initial injection of leuprolide acetate (L). Blood samples for prostatic specific antigen (PSA), testosterone (T), and luteinizing hormone were collected before CMA and DES-P administration, before and at 2, 7, 14, 28, 56, and 84 days after the first administration of leuprolide. The treatment with DES-P and CMA prior to LH-RH agonist induced an early decline of PSA. The mean PSA level showed no significant secondary rise in those patients with pretreatment after L administration. In the patients pretreated with DES-P or CMA, the mean serum T level never exceeded the pretreatment baseline after L administration. On the other hand, in the patients without DES-P or CMA, both serum T and PSA levels increased after the first administration of L. These results clearly demonstrate that pretreatment with DES-P 300 mg daily or CMA 100 mg daily for 2 weeks is quite effective to prevent disease flare after the first administration of L in patients with prostatic cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|